I. Sugitani

发表

TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling

K. Horie-Inoue, S. Inoue, K. Kinowaki, 2017, International journal of molecular sciences.

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.

Takao Takahashi, T. Hasebe, T. Yamane, 2015, Japanese journal of clinical oncology.

Fibrotic focus: An important parameter for accurate prediction of a high level of tumor‐associated macrophage infiltration in invasive ductal carcinoma of the breast

T. Hasebe, E. Arai, S. Ueda, 2017, Pathology international.

TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling

K. Horie-Inoue, S. Inoue, K. Kinowaki, 2017, International journal of molecular sciences.

A Case of Complete Resection of Locally Advanced Breast Cancer Resistant to Preoperative Chemotherapy by Radical Mastectomy, with Thoracic Wall Resection and Latissimus Dorsi Myocutaneous Flap Reconstruction

N. Fujiuchi, T. Hasebe, H. Nitanda, 2017 .

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety

N. Fujiuchi, Takao Takahashi, T. Hasebe, 2017, International Journal of Clinical Oncology.

Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

T. Hasebe, T. Yamane, S. Ueda, 2018, Breast Cancer Research.

Axillary ultrasound examination is useful for selecting patients optimally suited for sentinel lymph node biopsy after primary systemic chemotherapy.

N. Fujiuchi, Takao Takahashi, T. Saeki, 2012, American journal of surgery.

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study

Takao Takahashi, S. Ueda, T. Saeki, 2015, BMC Cancer.